IBKR Underperforms Peers as Analysts Diverge on Target After Q3 Slip

Interactive Brokers fell 5.2% on the week to $82.91, a steeper drop than the median 3.8% decline across its closest peers, with HOOD the only name worse off at down 11.1%. MS lost 3.3%, GS fell less than 1%, and STT dropped 4.3%. IBKR's 8.6% decline over the past month puts it near the bottom of the group on that measure too, though the stock recovered 1.9% on Tuesday, closing at $82.91 after touching lows following the October 15 earnings release.

The analyst response to Q3 results was split rather than uniformly cautious. Barclays raised its target to $117 from $115 on October 16, maintaining Overweight, while BMO Capital cut its target to $100 from $105 on the same day, staying at Outperform. Those two moves land on opposite sides of the same reaction to the same print. UBS trimmed its target modestly to $101 from $102 a week earlier, keeping its Neutral rating, while Bank of America and Wells Fargo both carry Overweight-equivalent ratings with targets of $116 and $102. Goldman Sachs holds a Buy at $113. The consensus is skewed toward constructive, with five holds and no underperforms across the tracked universe, and a mean price target of $104.66 against the current price of $82.91, implying roughly 26% upside. IBKR's analyst recommendation differential ranks in the 99th percentile of its universe, suggesting the Street is more uniformly positive on this stock than almost any other. EPS momentum over 30 and 90 days ranks in the 91st and 84th percentiles respectively, and the stock's dividend score ranks in the 88th.

Short interest has settled around the elevated levels that built up ahead of earnings and has not moved materially since. It sits at 3.1% of the free float, up 30% from a month ago but essentially flat over the past week, with day-to-day changes of less than 0.2%. The position remains large by recent history but the borrow market gives no sign of stress behind it. Availability is effectively unlimited, with roughly 281 million shares available to lend against a short position of around 13.6 million. Cost to borrow is only 0.43%, up 21% on the week but still within a range that has prevailed since September. The ORTEX short score is 34.5, reflecting a moderately low short-interest setup with no squeeze pressure. Options positioning is close to neutral, with the put/call ratio at 0.76, almost exactly in line with its 20-day average of 0.75 and well below the 52-week high of 0.93.

The ownership picture has its own wrinkle. BlackRock's 13G/A filing from October 17, 2025 showed a stake of 6.2%, down from 9.5% previously, though its reported institutional holding as of September 30 this year is 7.3%. Vanguard's 13G/A from March 2026 shows a stake recorded at 0%, while a separate Vanguard Capital Management filing from April 2026 shows 7.3%, suggesting different entities within the Vanguard structure hold positions that are not directly comparable across filings. These are event-driven disclosures around the 5% threshold and positions are as last disclosed. The most recent director purchase on record is a 25-share, plan-driven buy by director Lori Conkling on October 1, at $85.42, the latest in a series of small monthly purchases under a 10b5-1 plan with no signal value beyond its mechanical consistency.

The price that matters now is less about short positioning, which is stable, and more about whether IBKR can recover the gap between $82.91 and the analyst target cluster that runs from $100 to $117. The next scheduled earnings event is January 19, 2027, and the stock's behaviour in the weeks between now and then, particularly how it trades relative to MS and GS on any broader financial sector moves, will be the clearest indicator of whether the post-Q3 discount narrows on its own or requires a fresh catalyst.